PLK1 and acute myeloid leukemia: Studies now completed with the Plk/PI3K pathways inhibitor Rigosertib (NCT00854646, NCT01167166) are awaiting results, while the sequential combination of its oral formulation after azacitidine for 21 days (NCT01926587) showed two responses in seven patients with R/R AML.